Navigation Links
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
Date:7/29/2013

BOULDER, Colo., July 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the fourth quarter and full year of fiscal 2013 on Wednesday, August 7, 2013 and hold a conference call to discuss those results on Thursday, August 8, 2013.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Conference Call InformationDate:Thursday, August 8, 2013Time:9:00 a.m. eastern timeToll-Free:(800) 447-0521Toll:(847) 413-3238Pass Code:35320184Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
3. Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
4. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
5. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
6. Array BioPharma Announces Proposed Public Offering of Convertible Debt
7. Two Array Invented MEK Inhibitors Showcased At ASCO
8. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
9. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
10. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
11. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):